Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
27 oct. 2022 08h00 HE
|
Mustang Bio, Inc.
MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) --...